Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Sight Sciences (Nasdaq: SGHT) will report fourth quarter and full year financial results for the period ended December 31, 2025 after market close on Wednesday, March 4, 2026.
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT) will report fourth quarter and full year financial results for the period ended December 31, 2025 after market close on Wednesday, March 4, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live webcast and archived replay will be available on the company's Investors page. The replay will be accessible for at least 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – SGHT
In the Feb 19 session, SGHT gained 3.99%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings release date
- March 4, 2026
- Q4 and full-year 2025 results after market close
- Fiscal year-end
- December 31, 2025
- Period covered by upcoming report
- Conference call time PT
- 1:30 p.m.
- Q4 and full-year 2025 results call (Pacific Time)
- Conference call time ET
- 4:30 p.m.
- Q4 and full-year 2025 results call (Eastern Time)
- Webcast replay window
- 90 days
- Archived webcast available after the event
Historical Context
-
Preliminary Q4 and 2025 revenue and cash usage details released.
-
Peer‑reviewed OMNI data showing IOP and medication reductions.
-
Q3 results with higher guidance and lower operating expenses.
-
COO and CFO appointments plus board composition changes.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2026 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
Media contact:
pr@SightSciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.